These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 38254780)

  • 21. Siglecs: A journey through the evolution of sialic acid-binding immunoglobulin-type lectins.
    Bornhöfft KF; Goldammer T; Rebl A; Galuska SP
    Dev Comp Immunol; 2018 Sep; 86():219-231. PubMed ID: 29751010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Siglecs as Therapeutic Targets in Cancer.
    Lim J; Sari-Ak D; Bagga T
    Biology (Basel); 2021 Nov; 10(11):. PubMed ID: 34827170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.
    Ibarlucea-Benitez I; Weitzenfeld P; Smith P; Ravetch JV
    Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34155121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins.
    Brinkman-Van der Linden EC; Varki A
    J Biol Chem; 2000 Mar; 275(12):8625-32. PubMed ID: 10722702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Siglec and anti-Siglec therapies.
    Murugesan G; Weigle B; Crocker PR
    Curr Opin Chem Biol; 2021 Jun; 62():34-42. PubMed ID: 33607404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7.
    van Houtum EJH; Kers-Rebel ED; Looman MW; Hooijberg E; Büll C; Granado D; Cornelissen LAM; Adema GJ
    Cell Mol Life Sci; 2023 May; 80(6):169. PubMed ID: 37253806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current Status on Therapeutic Molecules Targeting Siglec Receptors.
    Lenza MP; Atxabal U; Oyenarte I; Jiménez-Barbero J; Ereño-Orbea J
    Cells; 2020 Dec; 9(12):. PubMed ID: 33333862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting sialylation to treat central nervous system diseases.
    Lünemann JD; von Gunten S; Neumann H
    Trends Pharmacol Sci; 2021 Dec; 42(12):998-1008. PubMed ID: 34607695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
    Daly J; Carlsten M; O'Dwyer M
    Front Immunol; 2019; 10():1047. PubMed ID: 31143186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells.
    Wang Z; Geng Z; Shao W; Liu E; Zhang J; Tang J; Wang P; Sun X; Xiao L; Xu W; Zhang Y; Cui H; Zhang L; Yang X; Chang X; Qiu X
    Cell Mol Immunol; 2020 Nov; 17(11):1148-1162. PubMed ID: 31754235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake.
    Jones C; Virji M; Crocker PR
    Mol Microbiol; 2003 Sep; 49(5):1213-25. PubMed ID: 12940982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.
    Adams OJ; Stanczak MA; von Gunten S; Läubli H
    Glycobiology; 2018 Sep; 28(9):640-647. PubMed ID: 29309569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viewing Siglecs through the lens of tumor immunology.
    Fraschilla I; Pillai S
    Immunol Rev; 2017 Mar; 276(1):178-191. PubMed ID: 28258691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-affinity ligands of Siglec receptors and their therapeutic potentials.
    Magesh S; Ando H; Tsubata T; Ishida H; Kiso M
    Curr Med Chem; 2011; 18(23):3537-50. PubMed ID: 21756229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Siglecs in Brain Function and Neurological Disorders.
    Siddiqui SS; Matar R; Merheb M; Hodeify R; Vazhappilly CG; Marton J; Shamsuddin SA; Al Zouabi H
    Cells; 2019 Sep; 8(10):. PubMed ID: 31546700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer.
    Wang J; Manni M; Bärenwaldt A; Wieboldt R; Kirchhammer N; Ivanek R; Stanczak M; Zippelius A; König D; Rodrigues Manutano N; Läubli H
    Front Cell Dev Biol; 2022; 10():828916. PubMed ID: 35309936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B Cell Siglecs-News on Signaling and Its Interplay With Ligand Binding.
    Meyer SJ; Linder AT; Brandl C; Nitschke L
    Front Immunol; 2018; 9():2820. PubMed ID: 30559744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of prognosis-related Siglecs in the glioma microenvironment.
    Mao R; Zhou L; Yang Y; Wang P; Lin H; Zheng J; Lv G; Zhou D
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3343-3357. PubMed ID: 34472004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Siglecs family used by pathogens for immune escape may engaged in immune tolerance in pregnancy.
    Chen Y; Chen H; Zheng Q
    J Reprod Immunol; 2023 Sep; 159():104127. PubMed ID: 37572430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Possible Influences of Endogenous and Exogenous Ligands on the Evolution of Human Siglecs.
    Angata T
    Front Immunol; 2018; 9():2885. PubMed ID: 30564250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.